Literature DB >> 3784698

Model-free evaluation and mean-time concept in pharmacokinetics.

D Brockmeier.   

Abstract

Pharmacokinetic characteristics may be separated into three classes: firstly, those which are truly independent of pharmacokinetic modelling - curve characteristics for instance, such as Cmax or tmax, but also organic clearance values; secondly, those which can be evaluated without an explicit pharmacokinetic model but under basic assumptions - characteristics such as total clearance, mean and variance of residence times or total volume of distribution; and thirdly, those which are bound to elaborate pharmacokinetic models, such as hybrid constants, micro-constants or partial volumes of distribution. It can be demonstrated that the second class - the model-independent evaluated characteristic - and the third are mutually transferrable; examples of this transcription are given. However, these purely theoretical considerations can only demonstrate that the second class is consistent with classic pharmacokinetic modelling. The usefulness of the model-independent evaluated characteristic is underlined by results of clinical pharmacological investigations in which this technique was applied. The topics addressed by these studies cover the problems of deep compartments, differences in absorption, influence of disease, drug interaction, and first-pass metabolization. Since the mean-time concept in particular is still controversial in the literature, some general theoretical explanations seem to be necessary.

Mesh:

Substances:

Year:  1986        PMID: 3784698

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  7 in total

1.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

3.  Estimation of permanence time, exit time, dilution factor, and steady-state volume of distribution.

Authors:  J Mordenti; A Rescigno
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

4.  A pharmacokinetic study of roxatidine acetate in chronic renal failure.

Authors:  N Lameire; B Rosenkranz; L Maass; D Brockmeier
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.

Authors:  D Brockmeier; P Hajdù; W Henke; E Mutschler; D Palm; W Rupp; H Spahn; M T Verho; A Wellstein
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Intra and interindividual variability in the kinetics of a poorly and highly metabolising solvent.

Authors:  J J Opdam
Journal:  Br J Ind Med       Date:  1989-12

7.  Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium.

Authors:  V Vlahov; M Badian; M Verho; N Bacracheva
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.